Elicio Therapeutics Inc (ELTX) Stock Price, Quote & News

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 209 0050

Website: elicio.com

Address:

451 D Street, 5th Floor Suite 501, Boston, United States

Doozio Apr. 26 at 3:22 PM

$ELTX ONTO 🐒🍌🧠⏰♾️

1 · Reply

Doozio Apr. 26 at 3:21 PM

$ELTX wen is data? A weekly sign ONTO 🐒🍌🧠⏰♾️?

1 · Reply

Cbra Apr. 25 at 7:16 PM

$ELTX Do you think Elicio has a good chance to run with solid phase 2 data since they need to raise so much money to help fund phase 3? It’s my major worry, I’ve been burnt before with other company’s when shares start getting dumped to help fill the coffers versus share price running because more investors are trying to get in. I could see this easily going 3/4/5x if they didn’t need the money, and I’m worried we only see a max of 2x if they start dumping shares to raise capital, then probably comes back down to its current price.

1 · Reply

Alt_Fuel Apr. 24 at 8:29 AM

$VSTM Verastem partner in KRAS ON / OFF " GenFleet Therapeutics " - New 52 Week High on April 24, 2026 $ANL $ELTX $ERAS $RVMD Apr. 23, 2026-- Verastem Oncology $VSTM will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-report-first-quarter-2026-financial-results

1 · Reply

Peligroso Apr. 22 at 2:43 PM

$SLS $RADX $ELTX are my biggest positions with near-term catalysts. Already booked 6 figures on SLS and RADX. Back in for the next run up!

0 · Reply

Alt_Fuel Apr. 20 at 5:42 PM

$VSTM $ANL $ELTX $ERAS $RVMD BTIG Reiterates Buy on Verastem, Maintains $19 Price Target 01:12 PM EDT, April 20, 2026 Updated 27 minutes ago, April 20, 2026 at 1:12 PM EDT 1:12 PM EDT, April 20, 2026 (Benzinga Newswire) BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $19 price target.

1 · Reply

Woooehoo Apr. 18 at 2:31 PM

$ELTX a lot of volume

1 · Reply

Cbra Apr. 16 at 2:29 PM

$ELTX I’m with you, just worried about potential dilution since they need to raise so much money for phase 3.

1 · Reply

justiceforb_85 Apr. 16 at 2:14 AM

$ELTX cannot wait for data relase!

0 · Reply

trenddetector Apr. 15 at 2:51 PM

$IBRX $IGLSI $ELTX built the tool I wish I had 16 years ago. If you or a loved one is facing a diagnosis, don't navigate it in the dark. www.YourCancerPath.com is a free, anonymous way to map out diagnostic steps and find live clinical trials without the medical jargon. Pass it on—it could be a lifeline for someone today.

0 · Reply

Elicio Therapeutics Reports Inducement Grants

Mar 12, 2026, 4:05 PM EDT - 6 weeks ago

Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 4, 2026, 1:10 PM EST - 7 weeks ago

Elicio Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 2 months ago

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Dec 11, 2025, 8:00 AM EST - 4 months ago

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

Nov 19, 2025, 8:00 AM EST - 5 months ago

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Nov 13, 2025, 4:01 PM EST - 5 months ago

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 7, 2025, 9:00 AM EST - 6 months ago

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

Nov 3, 2025, 8:00 AM EST - 6 months ago

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

Sep 29, 2025, 8:00 AM EDT - 7 months ago

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Sep 17, 2025, 8:00 AM EDT - 7 months ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 9 months ago

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Jun 25, 2025, 2:00 PM EDT - 10 months ago

Elicio Therapeutics Transcript: Status Update

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Jun 4, 2025, 8:00 AM EDT - 11 months ago

Elicio Therapeutics Secures $10 Million in Financing

May 13, 2025, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 16, 2025, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Jan 22, 2025, 7:30 AM EST - 1 year ago

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Dec 12, 2024, 7:00 AM EST - 1 year ago

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Sep 13, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

May 23, 2024, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 15, 2024, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Mar 29, 2024, 8:30 AM EDT - 2 years ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Mar 6, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Feb 5, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Jan 17, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Jan 16, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Jan 9, 2024, 6:00 AM EST - 2 years ago

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Dec 22, 2023, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Dec 4, 2023, 8:00 AM EST - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 9, 2023, 4:30 PM EST - 2 years ago

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 3, 2023, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting

Sep 27, 2023, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Doozio Apr. 26 at 3:22 PM

$ELTX ONTO 🐒🍌🧠⏰♾️

1 · Reply

Doozio Apr. 26 at 3:21 PM

$ELTX wen is data? A weekly sign ONTO 🐒🍌🧠⏰♾️?

1 · Reply

Cbra Apr. 25 at 7:16 PM

1 · Reply

Alt_Fuel Apr. 24 at 8:29 AM

1 · Reply

Peligroso Apr. 22 at 2:43 PM

$SLS $RADX $ELTX are my biggest positions with near-term catalysts. Already booked 6 figures on SLS and RADX. Back in for the next run up!

0 · Reply

Alt_Fuel Apr. 20 at 5:42 PM

1 · Reply

Woooehoo Apr. 18 at 2:31 PM

$ELTX a lot of volume

1 · Reply

Cbra Apr. 16 at 2:29 PM

$ELTX I’m with you, just worried about potential dilution since they need to raise so much money for phase 3.

1 · Reply

justiceforb_85 Apr. 16 at 2:14 AM

$ELTX cannot wait for data relase!

0 · Reply

trenddetector Apr. 15 at 2:51 PM

0 · Reply

ConsulHorkos Apr. 15 at 1:07 PM

$ELTX looking forward to the Ph2 data and being told how thy are going to pay for Ph3

1 · Reply

Alt_Fuel Apr. 15 at 9:07 AM

$VSTM $ANL $ELTX $ERAS $RVMD American Association for Cancer Research (AACR) Annual Meeting - April 17–22, 2026 Presentations: $VSTM - Multiple presentations (April 20-22) covering preclinical work on RAF, MEK, and FAK inhibition in melanoma, and pre-clinical data on the KRAS G12D inhibitor VS-7375 (including Abstract #lb183/LB197, showing strong tumor reduction in pancreatic cancer models) The above are related to the VSTM and GenFleet Therapeutics ... Verastem has license outside of China GenFleet’s oral KRAS G12D inhibitor GFH375 secured a second Breakthrough Therapy Designation in China for metastatic pancreatic cancer. NOTE - Latest Official News - April 8, 2026 at 8:08 PM ... GenFleet’s KRAS G12D Drug Wins Second Breakthrough Tag as First Pancreatic Cancer Monotherapy in China ... BTD in PDAC by CDE for GFH375, following BTD in NSCLC in March 2026 !!!

0 · Reply

Alt_Fuel Apr. 14 at 9:08 AM

$VSTM $ANL $ELTX $ERAS $RVMD American Association for Cancer Research (AACR) Annual Meeting - April 17–22, 2026 Presentations: $VSTM - Multiple presentations (April 20-22) covering preclinical work on RAF, MEK, and FAK inhibition in melanoma, and pre-clinical data on the KRAS G12D inhibitor VS-7375 (including Abstract #LB183/LB197, showing strong tumor reduction in pancreatic cancer models) The above are related to the VSTM and GenFleet Therapeutics ... Verastem has license outside of China GenFleet’s oral KRAS G12D inhibitor GFH375 secured a second Breakthrough Therapy Designation in China for metastatic pancreatic cancer. NOTE - Latest Official News - April 8, 2026 at 8:08 PM ... GenFleet’s KRAS G12D Drug Wins Second Breakthrough Tag as First Pancreatic Cancer Monotherapy in China ... BTD in PDAC by CDE for GFH375, following BTD in NSCLC in March 2026 !!!

0 · Reply

Alt_Fuel Apr. 10 at 11:57 AM

$VSTM 07 April 2026 "New drugs take aim at one of cancer’s deadliest mutations" "Mutations in the KRAS protein were once deemed ‘undruggable’. Today, various approaches are in the pipeline." - Via Nature Magazine - April 7, 2026 ... Bottom line: The article captures the momentum—G12D (biggest unmet need in PDAC/CRC) and pan/multi-RAS approaches are the hot frontier, with 2026 packed with data catalysts across these names. $RVMD and $VSTM are most directly “pure-play” on the new waves; $ERAS brings pan-KRAS innovation; $ELTX / $TNGX add immune/synthetic-lethal angles https://x.com/i/grok?conversation=2042570438279143494

0 · Reply

Alt_Fuel Apr. 10 at 11:47 AM

$VSTM 07 April 2026 "New drugs take aim at one of cancer’s deadliest mutations" "Mutations in the KRAS protein were once deemed ‘undruggable’. Today, various approaches are in the pipeline." Via Nature Magazine ... https://www.nature.com/articles/d41586-026-01016-7?utm_source=x&utm_medium=social&utm_campaign=nature&linkId=61297528 $VSTM $ELTX $ERAS $RVMD

0 · Reply

Alt_Fuel Apr. 9 at 12:28 PM

$VSTM $ANL $ELTX $ERAS $RVMD Genfleet Therapeutics announced on April 8, 2026, that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to its drug candidate, GFH375 (also known as HRS-4642). Verastem Oncology ($VSTM) is directly involved in this news. While GenFleet Therapeutics announced the breakthrough designation in China, Verastem holds the exclusive license to develop and commercialize GFH375 (referred to as VS-7375 in the U.S.) in all markets outside of mainland China, Hong Kong, Macau, and Taiwan.

0 · Reply

Alt_Fuel Apr. 9 at 10:59 AM

$VSTM $ANL $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to the VSTM collaboration with GenFleet Therapeutics ... NOTE - Latest Official News - April 8, 2026 at 8:08 PM ... GenFleet’s KRAS G12D Drug Wins Second Breakthrough Tag as First Pancreatic Cancer Monotherapy in China ... BTD in PDAC by CDE for GFH375, following BTD in NSCLC in March 2026 !!! This is licensed to Verastem outside of China GenFleet’s oral KRAS G12D inhibitor GFH375 secured a second Breakthrough Therapy Designation in China for metastatic pancreatic cancer. GFH375 has entered the world’s first phase III trial of an oral KRAS G12D inhibitor, bolstering GenFleet’s position in precision oncology. https://www.tipranks.com/news/company-announcements/genfleets-kras-g12d-drug-wins-second-breakthrough-tag-as-first-pancreatic-cancer-monotherapy-in-china

1 · Reply

Alt_Fuel Apr. 1 at 11:07 AM

$VSTM $ANL $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to the VSTM collaboration with GenFleet Therapeutics ...

1 · Reply

humdime Apr. 1 at 10:37 AM

Today $ELTX will be presenting at the World Vaccine Congress Washington 2026: “Targeting mKRAS with ELI-002 Cancer Vaccine – Clinical Updates” 12:40 PM Key efficacy data are unlikely to be fully disclosed, but it looks like there could be some new insights or updates shared.

1 · Reply

Alt_Fuel Mar. 31 at 3:15 PM

$VSTM $ELTX $ERAS $RVMD Verastem making Presentations - April 10 to 13, 2026 related to collaboration with GenFleet Therapeutics ...

0 · Reply

Cbra Mar. 30 at 5:49 PM

$ELTX which would be a “positive” from what they are saying, the longer it takes means there’s good data behind the treatment……..so, I’m praying that’s the case!

0 · Reply

Woooehoo Mar. 30 at 3:53 PM

$ELTX we gonna get data in June at this point

0 · Reply

Market Cap	215.05M
Revenue (ttm)	0.00
Net Income (ttm)	-39.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	5.74

Volume	74,900
Avg Vol	131,728
Day's Range	N/A - N/A
Shares Out	18.40M
Stochastic %K	28%
Beta	1.11
Analysts	Strong Sell
Price Target	$17.33